Today, the lack of timely testing capabilities in biopharma manufacturing can cost companies millions. Biopharmaceutical manufacturers must manage the risk of microbial contaminants — but the solutions on the market aren’t fast, easy to use, or accurate enough.
Enter LexaGene. This company’s cutting edge technology for human and animal biopharma manufacturing is redefining a major industry.
LexaGene is a molecular testing company pioneering MiQLab®1, a rapid, automated pathogen detection system designed to revolutionize microbial contaminant detection. The proceeds of this financing will be used to create the 2nd generation system to meet the unmet needs of the biopharma manufacturing industry.
Tackling a manufacturing microbial contamination detection market with an estimated annual TAM of ~$2.0 billion2, LexaGene is on track to solve real, costly problems for biopharma manufacturers.
Accredited investors only stand to win.
LexaGene is running an exclusive webinar for accredited investors on Monday, March 18th, 2024 at 2 PM ET. The event will be hosted by LexaGene CEO Tom Forte, as well as the company’s CTO, Dr. Jack Regan.
Sign up today to hear more about their leading class technology, the market opportunity, and how investors will benefit.
1 MiQLab® Systems shown are the current model which will serve as the basis for rebuilding the next generation system.
2 Commissioned market research conducted by Fletcher Spaght Inc.
This message is a paid advertisement sent on behalf of LexaGene, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
No comments:
Post a Comment